U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C8H18N2O2.C3H2O4.Pt
Molecular Weight 471.37
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EPTAPLATIN

SMILES

[Pt++].[O-]C(=O)CC([O-])=O.[H][C@]1(CN)OC(O[C@]1([H])CN)C(C)C

InChI

InChIKey=XJXKGUZINMNEDK-GPJOBVNKSA-L
InChI=1S/C8H18N2O2.C3H4O4.Pt/c1-5(2)8-11-6(3-9)7(4-10)12-8;4-2(5)1-3(6)7;/h5-8H,3-4,9-10H2,1-2H3;1H2,(H,4,5)(H,6,7);/q;;+2/p-2/t6-,7-;;/m1../s1

HIDE SMILES / InChI
Eptaplatin (also known as Heptaplatin) is a third-generation platinum antitumor drug, which has been approved for the clinical treatment of advanced gastric cancer in Korea. Although the anticancer mechanism of eptaplatin has not been studied well, it is supposed to be similar to that of cisplatin and oxaliplatin. Eptaplatin may bind to DNA to form various types of adducts, thus leading to cell death.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
SUNPLA

Approved Use

Treatment of progressive, metastatic or post-operative relapsing gastric cancer combined with 5-fluorouracil.

Launch Date

1999
PubMed

PubMed

TitleDatePubMed
Combination chemotherapy of heptaplatin, paclitaxel and 5-fluorouracil in patients with advanced gastric cancer: a pilot study.
2004 Jun
Combination chemotherapy with 5-fluorouracil and heptaplatin as first-line treatment in patients with advanced gastric cancer.
2004 Jun
Molecular mechanisms of heptaplatin effective against cisplatin-resistant cancer cell lines: less involvement of metallothionein.
2004 Oct 19
Combined effect of heptaplatin and ionizing radiation on human squamous carcinoma cell lines.
2005 Feb 28
Randomized, multicenter, phase III trial of heptaplatin 1-hour infusion and 5-fluorouracil combination chemotherapy comparing with cisplatin and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer.
2009 Mar
Patents

Sample Use Guides

Patients received eptaplatin (400 mg/m2) as a 1-hour continuous infusion on day 1, followed by 5-FU (1,000 mg/m2/day) as a 12-hour continuous infusion on days 1-5 every 4 weeks.
Route of Administration: Intravenous
In a cytotoxicity assay, SNU-601 cells were treated with 1-10000 ng/ml eptaplatin for 24 hr.
Name Type Language
EPTAPLATIN
INN   MART.   WHO-DD  
INN  
Official Name English
EPTAPLATIN [MART.]
Common Name English
CIS-((4R,5R)-2-ISOPROPYL-1,3-DIOXOLANE-4,5-BIS(METHYLAMINE)-N,N')(MALONATO(2-)-O,O')PLATINUM
Common Name English
NSC-D-644591
Code English
Eptaplatin [WHO-DD]
Common Name English
eptaplatin [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1450
Created by admin on Fri Dec 15 15:36:11 GMT 2023 , Edited by admin on Fri Dec 15 15:36:11 GMT 2023
Code System Code Type Description
INN
7986
Created by admin on Fri Dec 15 15:36:11 GMT 2023 , Edited by admin on Fri Dec 15 15:36:11 GMT 2023
PRIMARY
SMS_ID
100000182101
Created by admin on Fri Dec 15 15:36:11 GMT 2023 , Edited by admin on Fri Dec 15 15:36:11 GMT 2023
PRIMARY
NCI_THESAURUS
C90924
Created by admin on Fri Dec 15 15:36:11 GMT 2023 , Edited by admin on Fri Dec 15 15:36:11 GMT 2023
PRIMARY
PUBCHEM
119378
Created by admin on Fri Dec 15 15:36:11 GMT 2023 , Edited by admin on Fri Dec 15 15:36:11 GMT 2023
PRIMARY
EPA CompTox
DTXSID20932874
Created by admin on Fri Dec 15 15:36:11 GMT 2023 , Edited by admin on Fri Dec 15 15:36:11 GMT 2023
PRIMARY
CAS
146665-77-2
Created by admin on Fri Dec 15 15:36:11 GMT 2023 , Edited by admin on Fri Dec 15 15:36:11 GMT 2023
PRIMARY
FDA UNII
1352HON1DH
Created by admin on Fri Dec 15 15:36:11 GMT 2023 , Edited by admin on Fri Dec 15 15:36:11 GMT 2023
PRIMARY